AllerPops Reduce Nasal Symptoms in Adult Volunteers With Allergic Rhinitis

NCT05956691 | Completed Phase 2

• 1 other identifier: 21-SAHSE-01
• Study Type: interventional
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to test AllerPops' effectiveness in people who suffer from allergic rhinitis. The main question\[s\]it aims to answer are:

1. 1.To assess the effectiveness of AllerPops on relieving nasal symptoms compared to the control group in volunteers with seasonal/year-long allergies during the first 7 days of the 21-day intervention period.
2. 2.To evaluate the safety of AllerPops administration in volunteers with seasonal/year-long allergies during a 21-day intervention period.

Conditions

Allergic Rhinitis

Keywords

allergies; pollen; allergic rhinitis; common allergies; seasonal allergies; yearlong allergies; food allergies; autoimmune; prebiotics; probiotic; natural allergy relief

Outcome Measures

Primary Outcomes (2)

• Allergy symptom changes measured by severity grade (0-3) in TNSS(Total Nasal Symptoms Score) Questionnaire.

  To assess the effectiveness of AllerPops on changing nasal symptoms in volunteers with seasonal/year-long allergies during the first 7 days of the 21-day intervention period. Total Nasal Symptoms Score (TNSS) Questionnaire in grades of 0-3: a method developed to assess allergic rhinitis symptoms, based on the administration of a questionnaire. According to this method, allergic rhinitis symptoms are scored from 0 to 3 (4 grades of severity). This assessment will be conducted at the D1, D7, D14 and D21.

  21-day

• Nasal air flow changes measured by liter per minute in PNIF (Peak Nasal Inspiratory Flow) measurement.

  To assess the effectiveness of AllerPops on altering nasal air flow in volunteers with seasonal/year-long allergies during the first 7 days of the 21-day intervention period. Peak Nasal Inspiratory Flow (PNIF) measured in liter per minute: Measures nasal flow for assessing nasal airway patency. This assessment will be conducted at the D1, D7, D14 and D21.

  21-day

Secondary Outcomes (2)

• Number of participants with treatment-related adverse events as assessed by monitoring of vital signs, complete blood count, and a comprehensive safety panel.

  21 days

• Changes in participants' oral microbiomes using 16S amplicon metagenomic sequencing.

  21 days

Study Arms (2)

Investigation

EXPERIMENTAL

Dosing Instructions 1. Brush teeth with water (no toothpaste). 2. Scrub tongue with warm, wet, washcloth from the back to the front until most of the white/yellow biofilm on the tongue is gone. 3. Gargle and swish hot (optimal 120°F) water for 10-20 seconds. Spit out and repeat gargling over the next 5 minutes. The tongue should be red and without any biofilm. If it is not, repeat Step 2, and gargle once more. 4. Self-administer one lozenge. Let the lozenge slowly melt in the mouth. Do not chew or swallow whole. This may take up to 60 minutes. Discard if it is not fully dissolved after 60 minutes. 5. Wash the washcloth to be ready before next use.

Dietary Supplement: AllerPops

Control

ACTIVE COMPARATOR

Dosing Instructions 1. Microwave: heat the product in 5 second increments until soft. (Caution: more than 10 seconds of microwaving the product may cause it to burn). 2. Cut: cut the product into smaller pieces 3. Swallow: swallow without chewing the pieces with warm water while they are still warm. It can be swallowed over time or at once.

Dietary Supplement: AllerPops

Interventions

AllerPops DIETARY_SUPPLEMENT

Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.

Control; Investigation

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Participants will be clinically diagnosed with persistent or intermittent allergic rhinitis, according to the Allergic Rhinitis and Its Impact on Asthma (ARIA) classification. (The guidelines of Allergic Rhinitis and its Impact on Asthma (ARIA) group, classified it to intermittent (less than 4 days per week and for less than 4 weeks) and persistent (more than 4 days per week or lasting more than 4 weeks regardless of the number of days per week).
• \. Male or female seasonal/year-long nasal allergy sufferers (as assessed by a questionnaire at screening) between the ages of 18 and 70.
• \. Females who are not of childbearing potential (post-menopausal defined as those with amenorrhea for at least 2 years). Females of childbearing potential should be either sexually inactive (abstinent) for 60 days prior to the first dose of the study, throughout the study and for 30 days after completion of the study, or be using one of the following acceptable methods of birth control: i. Surgically sterile (bilateral tubal-ligation, hysterectomy, bilateral oophorectomy) for at least 90 days prior to the first dose of the study.
• ii. IUD in place for at least 60 days prior to the first dose of the study, throughout the study and for 30 days after completion of the study.
• iii. Barrier methods (condom, diaphragm) with spermicide for at least 60 days prior to the first dose of the study, throughout the study and for 30 days after study completion.
• iv. Hormonal contraceptives for at least 90 days prior to the first dose of the study, throughout the study, and for 30 days after study completion.
• Changes to the method of birth control while participating in the study will be judged by the PI for acceptability.
• \. Written informed consent obtained and signed by participant. 5. BMI between 18.5 and 29.9 kg/m2, with a stable weight over the last 3 months. (A stable weight is defined as \<5% of total body weight change in the last 3 months).
• \. Agrees not to use any over the counter, prescription, health supplement or dietary supplement from at least 14 days prior to screening until the end of the study.
• \. Agrees to maintain current dietary habits, level of physical activity, occupational and living environment for the trial duration.
• \. Does not regularly consume more than 2 standard\* alcoholic beverages a day as assessed through verbal confirmation at screening, and agrees not to consume \>2 standard\* alcoholic beverages per day for the trial duration.
• \. Non-smoker within 12 months prior to dosing as assessed by verbal confirmation.
• \. Stable medical conditions that do not require medication use routinely and do not affect or involve the immune systems as determined by medical history, physical examination, clinical chemistry performed at screening, and as assessed by the Principal Investigator.
• \. Agrees not to use nasal steroid spray from at least 14 days prior to screening until the end of the study.
• \. Agrees not to use neti-pot and oil-pulling for at least 7 days prior to screening until the end of the study.

You may not qualify if:

• Participants who are pregnant/lactating or planning to become pregnant during the course of the clinical trial.
• Participants who have any sings of active or recurrent upper airway infection (bacterial/viral).
• Participants who have a known sensitivity or allergy to any of the study products, or ingredients.
• Participation in another research study within 30 days prior to enrollment in this clinical trial.
• Participants who are not able to tolerate venipuncture and/or have poor venous access.
• Participants dependent on decongestants (nasal or oral) or receiving allergen-specific immunotherapy.
• Participants who have been diagnosed with other clinical forms of rhinitis such as infectious rhinitis, rhinitis of pregnancy, food and alcohol-induced rhinitis, atrophic rhinitis, vasomotor rhinitis, rhinosinusitis and age-related rhinitis.
• Participants who have receive previous acupuncture treatment or alternative medicine for AR in the last three months or planned in the next two years.
• Participants who have received allergy desensitization therapy (current, during the past two years, or planned in the next two years).
• Participants who have had any major surgery within 1 year of enrollment into the clinical trial or have any anticipated major surgeries intended to occur during the clinical trial.
• Participants who have received a blood transfusion within 8 weeks of enrollment in the clinical trial.
• Participants who have donated blood or plasma to a blood bank or clinical study within 8 weeks of enrollment and during the study except venipuncture as part of clinical trial.
• Participant has known severe medical conditions, such as cardiovascular, liver or renal dysfunction, diabetes mellitus, cancers, cerebrovascular diseases, blood system diseases which in the opinion of the Principal Investigator, may preclude safe study participation, or interfere with study objectives.
• Participants who are immunocompromised or have been diagnosed HIV/AIDS, Hepatitis B, or untreated Hepatitis C.
• Participants with Grade II or III septum deviation and/or presence of nasal polyps or other conditions that lead to nasal obstruction.

Sponsors & Collaborators

• AllerPops Corp: lead

Study Sites (1)

Dicentra

Toronto, Ontario, M5S 2B7, Canada

Location

Related Publications (1)

• Shunsheng Han C. Prebiotic supplements correct oral probiotic deficiency for lasting allergy relief. Am J Transl Res. 2024 Jan 15;16(1):136-146. doi: 10.62347/JWOU4205. eCollection 2024.

  PMID: 38322553 DERIVED

MeSH Terms

Conditions

Rhinitis, Allergic; Hypersensitivity; Rhinitis, Allergic, Seasonal; Food Hypersensitivity

Condition Hierarchy (Ancestors)

Rhinitis; Nose Diseases; Respiratory Tract Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Immune System Diseases

Study Officials

• Raj Gurinder, MD

  Independent

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 16, 2023
• First Posted: July 21, 2023
• Study Start: April 5, 2022
• Primary Completion: September 5, 2022
• Study Completion: September 21, 2022
• Last Updated: July 24, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)